Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32

Biodesix, Inc.

Biodesix, Inc.

BDSX

0.00

Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ: BDSX) with a Buy rating and announces Price Target of $32.